Navigation Links
Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
Date:4/26/2012

2012 as a result of higher prescription demand, due to an increase in VYVANSE's market share and growth in the US ADHD market (+10%), and the effect of a price increase taken since Q1 2011. These positive factors were partially offset by higher sales deductions as a percentage of gross product sales in Q1 2012 compared to Q1 2011.

REPLAGAL - Fabry disease

REPLAGAL product sales growth was driven by the treatment of new patients, being both naïve patients and switches from FABRAZYME®. Reported REPLAGAL sales were impacted by unfavourable foreign exchange, due to the stronger US dollar in Q1 2012 compared to Q1 2011.

ELAPRASE- Hunter syndrome

Product sales for ELAPRASE increased as a result of increased patients on therapy across all regions in which ELAPRASE is sold and also benefited from the timing of certain large orders from markets which order less frequently. Reported ELAPRASE sales were also impacted by unfavourable foreign exchange.

ADDERALL XR - ADHD

ADDERALL XR product sales in Q1 2012 remained constant compared with Q1 2011, as higher US prescription demand was offset by an increase in sales deductions in Q1 2012.

For the full year we expect ADDERALL XR's sales deductions as a percentage of branded gross sales to be between 60% and 65%.

LIALDA/MEZAVANT - Ulcerative colitis

The growth in product sales for LIALDA/MEZAVANT in Q1 2012 primarily resulted from higher US prescription demand following increases in US market share and a price increase taken since Q1 2011, offset by higher de-stocking in Q1 2012 compared to Q1 2011.

VPRIV - Gaucher disease

VPRIV product sales growth was driven by the treatment of new patients, being both naïve patients and switches from CEREZYME®. Reported VPRIV sales were also impacted by unfavourable foreign exchange.

INTUNIV - ADHD

INTUNIV product sales were up 63% compared to Q1 2011,
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Insulin ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... , , , CARLSBAD, Calif., ... today its intention to file a Special Protocol Assessment (SPA) with ... on its lead drug, DCCR, for the treatment of very high ... primary efficacy endpoint assessed at 12 weeks. This decision followed ...
... , , , ... ANDS ) today announced viral load data for the final cohort of ... Company,s oral inducer of endogenous interferons that acts via the toll-like receptor ... other day over 10 days, the mean (+/-SEM) maximal decline in viral ...
Cached Medicine Technology:Essentialis to Submit SPA for Hypertriglyceridemia 2ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients 2ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients 3ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients 4ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients 5
(Date:4/24/2014)... On April 28, the Center for BrainHealth will ... our most pressing brain-related challenges at its inaugural ... Resilience and Regeneration." Featured speakers will include Dr. ... the Center for BrainHealth, U.S. Senator Chuck Grassley ... Doggett, Deputy Assistant Secretary for Policy and Early ...
(Date:4/24/2014)... more than one out of three survivors of ... in The Lancet Respiratory Medicine , and ... rather than mentally. , It is one of ... and functional outcomes of critical care survivors, according ... of Medicine, and it highlights a significant public ...
(Date:4/24/2014)... Foundation has awarded LSU Health Sciences Center New ... grant in the amount of $295,635. The funding ... social and educational backgrounds, underrepresented in the sciences, ... project will provide students with training for 10 ... will be led by Principal Investigator Dr. Fern ...
(Date:4/23/2014)... 24, 2014 Pregnant immigrants from Sub-Saharan Africa, ... monitoring during pregnancy, according to new research from ... in the British Journal of Obstetrics and ... eclampsia rates among immigrants and native-born women in ... Denmark, Sweden, Spain (Catalonia and Valencia) and the ...
(Date:4/23/2014)... April 23, 2014 The American Society for Radiation ... Role of Postoperative Radiation Therapy for Endometrial Cancer: ... of adjuvant radiation therapy in the treatment of ... in the May-June 2014 issue of Practical ... journal of ASTRO. The full-length guideline is available ...
Breaking Medicine News(10 mins):Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3
... are readmitted within a year, study finds , , WEDNESDAY, ... patients discharged from the hospital is readmitted within 30 ... within a year, a new study finds. , The ... problem that researchers believe could be prevented through better ...
... Extreme Physical Performance (EP2), a sport supplement firm, has ... that manufactures a new generation of safe and effective ... human physical performance. Together, they will bring innovative new ... gym goers. TORABOLIC is Indus,s first new novel ingredient ...
... YORK, April 1 Spring may be synonymous ... for Alex Mele of Coram, NY, a 15-year-old baseball player ... a fight to shut out cancer.Mele, a catcher and third ... Junior Varsity Baseball Team, suddenly fell ill last November. ...
... SAN DIEGO, April 1 Gen-Probe (Nasdaq: ... its co-respondents F. Hoffmann-La Roche Ltd. and Roche Molecular ... (now Qiagen) concerning the Company,s supply and purchase agreement ... , Earlier today, a three-member arbitration panel ...
... Touch(TM) hearing aid is smallest receiver-in-canal product availableSALT LAKE ... SNCI ) will celebrate its first receiver-in-canal ("RIC") ... be held in Dallas, Texas, April 2 through 4, ... is the smallest receiver-in-canal product available in the market. ...
... 1 Novavax Inc. (Nasdaq: NVAX) announced ... of 12.5 million shares of Novavax,s common stock at $0.88 per ... of the new strategic alliance between Novavax and Cadila. Novavax intends ... to pay a portion of its 4.75% senior convertible notes due ...
Cached Medicine News:Health News:High Rate of Rehospitalizations Costing Billions 2Health News:High Rate of Rehospitalizations Costing Billions 3Health News:New Sports Supplement Company to Partner with Indus Biotech 2Health News:Blood, Marrow Drive Offers Hope for Baseball Player, 15 2Health News:Gen-Probe, Roche Prevail in Arbitration With Digene Concerning Human Papillomavirus Agreement 2Health News:Gen-Probe, Roche Prevail in Arbitration With Digene Concerning Human Papillomavirus Agreement 3Health News:Sonic Innovations Celebrates Company's First Receiver-In-Canal Hearing Aid 2Health News:Sonic Innovations Celebrates Company's First Receiver-In-Canal Hearing Aid 3Health News:Novavax Announces Closing of $11 Million Common Stock Sale to Subsidiary of Cadila Pharmaceuticals 2
... proven to be a successful alternative ... knee arthroplasty with proper indications. The ... unicompartmental knee system developed to streamline ... latest conservative surgical techniques with the ...
... Knee CR system was designed to ... femoral joint has a recessed, deepened ... advancement of the patella, which has ... The anatomic groove promotes more normal ...
The Biopro Modular TKO implant is among the thinnest bone conserving Posterior Cruciate Ligament sparing knees available. It provides all the benefits of the Biopro TKO implant and gives the option o...
... PowerSuite™ holmium laser combines excellent cutting, ... virtually bloodless procedures. It is also ... gall bladder stones of all compositions, ... tool. Because its laser light is ...
Medicine Products: